Enliven Therapeutics, Inc. $ELVN Shares Acquired by Profund Advisors LLC

Profund Advisors LLC raised its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 260.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 27,874 shares of the company’s stock after acquiring an additional 20,148 shares during the quarter. Profund Advisors LLC’s holdings in Enliven Therapeutics were worth $1,278,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ELVN. BlackRock Inc. acquired a new position in Enliven Therapeutics during the 2nd quarter worth $221,255,000. First Light Asset Management LLC increased its holdings in Enliven Therapeutics by 574.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after purchasing an additional 1,158,883 shares during the period. Assenagon Asset Management S.A. raised its position in Enliven Therapeutics by 276.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock valued at $52,898,000 after purchasing an additional 847,399 shares in the last quarter. Rock Springs Capital Management LP raised its position in Enliven Therapeutics by 3.5% in the 1st quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company’s stock valued at $32,399,000 after purchasing an additional 28,095 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at about $30,617,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total value of $231,572.64. Following the sale, the chief financial officer owned 38,000 shares in the company, valued at $1,462,240. This represents a 13.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the transaction, the director directly owned 13,000 shares of the company’s stock, valued at $606,710. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 31,054 shares of company stock worth $1,493,823 in the last ninety days. 3.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on ELVN. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Stifel Nicolaus upped their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Thursday, October 15th. Zacks Research cut shares of Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Finally, JPMorgan Chase & Co. began coverage on shares of Enliven Therapeutics in a research note on Thursday, October 1st. They issued an “overweight” rating and a $75.00 price target for the company. Ten analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $75.44.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $44.63 on Tuesday. The company’s 50 day simple moving average is $48.40 and its 200-day simple moving average is $42.67. Enliven Therapeutics, Inc. has a 12-month low of $14.78 and a 12-month high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.79 earnings per share for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.